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New evidence has been emerging that antibodies can be protective in various
experimental models of tuberculosis. Here, we report on protection against multidrug-
resistant Mycobacterium tuberculosis (MDR-TB) infection using a combination of the
human monoclonal IgA 2E9 antibody against the alpha-crystallin (Acr, HspX) antigen and
mouse interferon-gamma in mice transgenic for the human IgA receptor, CD89. The effect
of the combined mucosal IgA and IFN-g; treatment was strongest (50-fold reduction)
when therapy was applied at the time of infection, but a statistically significant reduction of
lung bacterial load was observed even when the therapy was initiated once the infection
had already been established. The protection involving enhanced phagocytosis and then
neutrophil mediated killing of infected cells was IgA isotype mediated, because treatment
with an IgG version of 2E9 antibody was not effective in human IgG receptor CD64
transgenic mice. The Acr antigen specificity of IgA antibodies for protection in humans has
been indicated by their elevated serum levels in latent tuberculosis unlike the lack of IgA
antibodies against the virulence-associated MPT64 antigen. Our results represent the first
evidence for potential translation of mucosal immunotherapy for the management of
MDR-TB.
Keywords: tuberculosis, IgA, mAb—monoclonal antibody, drug resistance, HspX, alpha crystallin, CD89 (Fc alpha/
muR), interferon-gammaINTRODUCTION
The evidence for a protective role of antibodies in tuberculosis (TB) has been strengthened
significantly over the last decade or so, owing to a number of recent reports (1–5). The common
theme in these reports is that under certain experimental conditions, some antibodies can exert
protective activity while others cannot, and this may depend on several factors including their
origin, isotype, and specificity, as well as posttranslational modifications. Thus, Li et al. (2) showed
that polyclonal antisera from some healthcare workers exposed to Mycobacterium tuberculosis who
were latently infected or uninfected, exerted a protective effect when transferred to mice prior to
challenge with M. tuberculosis. Furthermore, the same study reported that antibodies fromorg October 2020 | Volume 11 | Article 5828331
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patients, and this appears to be a common theme emerging from
the most recent studies. Thus, Lu et al. (3), also reported that
antibodies from individuals with latent M. tuberculosis infection
were superior to those from active TB patients in their capacity to
mediate intracellular killing of the bacteria by macrophages. This
was associated with distinct glycosylation profiles of these
antibodies which conferred superior functional properties and
in particular enhanced interaction with the immunoglobulin Fc
receptors on phagocytic cells.
In addition to their specificity, another feature of antibodies
that may influence their function in M. tuberculosis infection is
their isotype. This was shown, when intranasal delivery of
murine IgA, but not IgG monoclonal antibodies (mAb) of the
same alpha crystalin (Acr) antigen specificity, when combined
with mouse interferon-g, imparted protection against M.
tuberculosis lung infection in mice (6, 7) and could also
prevent post-chemotherapy relapse of infection and lung
pathology (6–9). The role of the IgA isotype was further
supported by demonstrating protection using a human IgA
mAb in CD89 human IgA-receptor transgenic mice (10).
Recently, the role of IgA isotype was shown by the finding
under in vitro conditions, that IgA antibodies specific for
lipoarabinomannan (LAM) and heparin-binding hemagglutinin
adhesin (HBHA) were bacteriostatic whereas IgG antibodies
exacerbated infection (5). This, however, may be epitope
dependent, since several other studies reported protective effects
of various IgG antibodies (11–14).
The synergy between the murine anti-Acr mAb TBA61 and
mouse IFN-g was previously demonstrated following their
intranasal inoculation, by better protection against intranasal
Mtb challenge and by bactericidal action and increased nitric
oxide and TNF production by mouse peritoneal macrophages in
vitro (8). The mechanisms involving both Fca-receptor and IFN-g
mediated macrophage functions were possibly related to the IgA
and IFN-g synergistic inhibition of the growth of J774 mouse
macrophage cell lines and the induction of TNF synthesis and
apoptosis of mouse peritoneal exudate macrophages (8).
Furthermore, we have previously shown that while IFN-g had
some inhibitory effect onMtb infection in CD89 transgenic mice,
the greatest protective effect was seen when mice were treated
with a combination of both 2E9IgA and IFN-g (10). A synergy
between antibody and IFN-g action in vitro was also reported for
another intracellular pathogen, Brucella melitensis (15). Other
possible mechanisms involving the IgA binding to the Gal-3
(Mac-2) intracellular lectin were also considered (16).
In the current study, we set out to explore the effectiveness of
combined IgA and IFN-g; immunotherapy (CIT) against MDR-
TB infection as the key step toward potential translation of this
approach for clinical application. MDR-TB is currently on the
rise and poses a significant challenge to the healthcare systems
around the world, but particularly in the developing countries,
which shoulder the biggest burden of both TB and MDR-TB.
While the new drugs such as bedaquiline (17) and delamanid
(18) hold promise, treatment of MDR-TB still remains difficult,
with long duration, significant drug toxicity and comparativelyFrontiers in Immunology | www.frontiersin.org 2inferior cure rates, all being unsatisfactory. An adjunct form of
immunotherapy such as CIT would therefore be highly desirable
against MDR-TB and also other resistant infections, as it could
improve these outcomes by acting on the ‘persister’ bacteria
resisting drug treatment, thus shortening the treatment duration
and improving the cure rates (19).
Using a transgenic mouse model expressing either human
IgA (CD89) or IgG (CD64) receptors (20), we demonstrate
effectiveness of IgA but not IgG and elucidate potential
mechanisms involved in protection. The specificity of the
2E9IgA1 mAb appears to be important, since its antigenic
target, the alpha crystallin (Acr, HspX, 16 kDa) was shown to
be expressed on the surface of mycobacteria, thus facilitating
2E9IgA1 mediated phagocytic uptake. Finally, we detected
similar levels of anti-Acr IgA antibodies not only in sera of TB
patients but, surprisingly, also of latently infected individuals
(LTBI) and healthy BCG vaccinated controls, suggesting
a potential role for IgA and Acr in the control of
M. tuberculosis infection.MATERIALS AND METHODS
Purification and Biophysical
Characterization of 2E9IgA1
Expression of 2E9IgA1 mAb in Chinese Hamster Ovary (CHO)
cells was previously described (10). To purify the antibody,
transfected CHO cells were grown in CellSTACK culture flasks
(Corning, Deeside, UK) kept at 37°C 5% CO2 to confluency in
DMEM medium (Sigma, Poole, UK) supplemented with 10% w/v
FBS (Sigma), 2 mM L-glutamine (Sigma), 100 units/ml of
penicillin, and 100 µg/ml of streptomycin (Sigma). Cell culture
supernatants were harvested, filter sterilized using 0.22 µm PES
filters (Millex, Sigma), and subjected to affinity chromatography
using a Capto L resin (GE Healthcare, Little Chalfont, UK) at a 2
ml/min flow rate. The resin was then washed with PBS, and
2E9IgA1 was eluted in 0.1 M glycine pH 2.5, followed by
immediate neutralization by addition of TRIS buffer pH 9.
Fractions containing protein were then pooled and dialysed
using a cassette (Thermo Scientific, UK) against PBS pH 7.4
overnight and concentrated using a 30 kDa cut-off centrifugal
concentrator (Amicon-Merck, Watford, UK). Purified 2E9IgA1
was characterized by SDS-PAGE using 4–12% BIS-TRIS gels
under non-reducing and reducing (b-mercaptoethanol)
conditions. The gels were stained using Coomassie blue
(Expedeon, Cambridge, UK) or blotted onto nitrocellulose
membranes and subsequently stained using horseradish
peroxidase (HRP) conjugated anti-human a or k chain
antibodies (The Binding Site, Birmingham, UK) and developed
using ECL Prime (Amersham, UK). Acr binding ELISA was
carried out by coating microplates (NUNC, Thermo Fisher
Scientific, UK) with 5 µg/ml of antigen and detecting antigen
specific IgA using HRP conjugated anti-human a-chain (The
Binding Site) secondary antibody. ELISA plates were developed
using SigmaFast OPD (Sigma) and absorbance was measured at
450 nm.October 2020 | Volume 11 | Article 582833
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2E9IgA1 was aerosolized by using the commercially available
Omron Micro Air U22 electronic mesh nebulizer (Omron,
Milton Keynes, UK). 1 ml of 100 µg/ml of 2E9IgA1 in either
PBS pH 7.4 alone or PBS containing 0.01% Tween-20 (Sigma)
were loaded into the fluid chamber and the exhaust sealed onto a
pre-weighed collection vessel at a 45° downward angle. The
nebulizer was then turned on and samples left to nebulise until
the fluid chamber was emptied. Once completed, the collection
vessel was then sealed and placed in ice to condense the
nebulized sample. The condensed sample was aspirated to
determine protein concentration by OD280. Acr and CD89
binding of pre- and post-nebulized samples were determined
by ELISA with samples loaded at equal protein concentration.
Production of 2E9IgG1
Plasmids were expanded and transfected into 293T cells. Cells
were plated at a density of 5.0 x 106 cells in 10 ml in a 10 cm dish.
10 ug of total DNA were transfected onto cells using 293 TransIT
(Mirus Bio, Madison, US) following manufacturer’s protocols.
Cells were washed 16 h post transfection and cultured with
FreeStyle™ 293 Expression media (Gibco, Thermo Fisher
Scientific). Cell culture supernatants containing protein were
harvested at 7 days post transfection. Antibodies within the
supernatants were bound to magnetic protein G beads (Merck,
St. Louis, MO), washed three times with PBS, eluted from the
beads, and neutralized using 1 M Tris, pH 8.0.
BCG Binding Assay
BCG Pasteur was grown in 7H9 media (Difco, Becton
Dickinson) supplemented with glycerol and stocks prepared
by sonication (Hielsher UP200St Vialtweeter, Teltow,
Germany) at 70% amplitude and 10 W in three 10 s bursts
and passing through a 70 µm cell strainer to remove clumps.
Escherichia coli was grown in standard LB broth. BCG and E.
coli samples were then re-suspended in FACS buffer consisting
of 0.5% w/v BSA (Sigma) in PBS to an OD600 of 0.35. IgA was
added at concentrations of 100, 20, 4, 0.8, and 0.2 µg/ml and
incubated at room temperature for 2 h. For Acr competition
assays, 2E9IgA1 concentration was 0.2 µg/ml, and Acr was also
added to the samples to final concentrations of 200, 1.6, and
0.064 µg/ml. After washing three times with FACS buffer,
samples were incubated with a FITC conjugated anti-human
IgA antibody (The Binding Site) for 1 h. Samples were then
washed a further three times with FACS buffer and acquired on
a BD FACSCalibur cytometer. Data was analyzed using
Flowjo V10.Persistence of Mucosally Applied 2E9IgA1
in Mice and Legendplex Assay
Human IgA receptor CD89 transgenic BALB/c mice were
housed at the St George’s University of London Biological
Research Facility and given food and water ad libitum. Some
animals were inoculated with 0.5 million colony forming units
(CFU) of BCG intranasally. Animals were then divided into 2
groups of 9, with the control group receiving 32.5 µl PBS and theFrontiers in Immunology | www.frontiersin.org 32E9IgA1 group receiving 50 µg of antibody and 1 mg of IFN-g;
per animal in 32.5 µl total volume. All treatments were given by
the intranasal route. Three animals were then culled by cervical
dislocation at 24, 48, and 72 h post treatment, and
bronchoalveolar lavage (BAL) was taken by injecting 1 ml of
PBS through the trachea and withdrawing three times. BAL
samples were then centrifuged at 14,000 RCF to remove debris.
Cytokine levels in the BAL fluid 24 h post-treatment were
determined using a Legendplex assay (Biolegend, San Diego,
US), acquired on a BD FACSCanto, and subsequently analyzed
using the Legendplex software (Biolegend). 2E9IgA1 in the BAL
fluid was determined by Acr ELISA, as described previously.
In Vitro Experiments
For studies of mechanisms of 2E9IgA1 modulation of infection,
beads or M. tuberculosis bacilli were used with human
macrophage/monocyte cell lines THP-1 and U937 (ATCC,
LGC Standards, Teddington, UK), or neutrophils from blood
of healthy volunteers, following ethical approvals. Neutrophils
were purified from blood using HetaSep (Stemcell, Cambridge,
UK) in a 1:5 ratio and incubated for 30 min to separate
leukocytes from erythrocytes. Subsequently, the white-coloured
layer of leukocytes was transferred to a fresh tube and
neutrophils were isolated using the direct human neutrophil
isolation kit (Stemcell) according to manufacturer’s instructions.
Neutrophils Phagocytosis
Biotinylated antigen was coupled to yellow-green Neutravidin
beads (Life Technologies, Thermo Fisher Scientific). 2E9IgA1
was diluted in culture medium and incubated with antigen-
coated beads for 2 h at 37°C. Freshly isolated neutrophils (5x104
cells/well) were incubated for 1 h at 37°C. Cells were stained for
CD66b (Clone G10F5; Biolegend), CD3 (Clone UCHT1; BD
Biosciences), and CD14 (Clone MP9; BD Biosciences), fixed with
4% paraformaldehyde, and analyzed by flow cytometry.
Neutrophils were defined as SSC-A high CD66b+, CD3-, and
CD14-. A phagocytic score was determined using the following
formula: (percentage of FITC+ cells)*(geometric mean
fluorescent intensity (gMFI) of the FITC+ cells)/10,000.
Monocyte Phagocytosis
Antigen-coated beads were generated as described for
neutrophils. 2E9IgA1 was diluted in culture medium and
incubated with antigen-coated beads for 2 h at 37°C. Unbound
antibodies were removed by centrifugation prior to the addition
of THP-1 cells at 2.5 x 104 cells/well. Cells were fixed with 4%
paraformaldehyde and analyzed by flow cytometry. A phagocytic
score was determined as described above.
Mycobacterial Inhibition Assay
U937 cells (100,000/well) in 96-well plates were infected withM.
tuberculosis at the multiplicity of infection (MOI) of 2:1. Cultures
were supplemented with either PBS, IFN-g; (20 ng/ml) or
2E9IgA1 (100 mg/ml) and IFN-g;. Five days later, the cultures
were treated for 2 h with 50 mg/ml of amikacin to kill
extracellular bacteria, after which the cells were lysed and the
intracellular infection quantified by plating on 7H11October 2020 | Volume 11 | Article 582833
Tran et al. Mucosal IgA Immunotherapy of TuberculosisMiddlebrook agar plates supplemented with OADC (Becton
Dickinson). To test the effect of neutrophils on infected
macrophages, murine J774 cells in 6-well plates (5 million
cells/well) were infected with M. tuberculosis at the MOI 2:1,
for 24 h. The cultures were then supplemented with human
neutrophils isolated from blood of healthy volunteers at the ratio
of neutrophils-to-macrophages 5:1. Either PBS or 2E9IgA1 (100
mg/ml) was also added to the cultures and after 24 h, amikacin
treatment performed. The cells were then lysed and plated for
CFU enumeration, as above.
Combined Immunotherapy of MDR-TB in
Transgenic Mice
All animals were used with approval from St George’s University
of London Ethics Committee under an approved UK Home
Office animal project licence and used in accordance with the
Animals (Scientific Procedures) Act 1986. 3–9-month-old CD89
and CD64 transgenic mice were used, both males and females.
Groups consisted of nine animals, following power calculations
based on the minimal anticipated magnitude of the effect of 0.5
log difference, 95% statistical power, and an average intra-group
variability from previous experiments of 1 log. Mice were housed
in containment level 3 facilities at the St George’s University of
London Biological Research Facility and challenged with MDR-
TB (clinical isolate from Peru, strain number 10095) at 100–200
CFU per animal by the nose-only aerosol system (Biaera
Technologies, Hagerstown, MD, US). Infectious dose per
animal was determined by sampling airflow during MDR-TB
challenge by the use of an impinger and enumeration of sample
by CFU. For animals receiving 2E9IgA1 treatment, CIT was
given either on the same day as MDR-TB challenge, 24 h or 7
days post-challenge, consisting of 50 µg/animal of 2E9IgA1 and 1
µg/animal of murine IFN-g per treatment. The treatment
regimens for all 2E9IgA1 experiments consisted of three
intranasal doses given at three-day intervals after the first
treatment. Animals receiving 2E9IgG1 started their treatment
regimen 24 h post-challenge. The first dose consisted of 20 µg/
animal of 2E9IgG1 + 1 µg/animal of IFN-g given intranasally.
The second dose consisting of 40 µg/animal of 2E9IgG1 + 2 µg/
animal of IFN-g was given intra-peritoneally, 3 days later. After
another 3 days, the final dose was given again intranasally, as the
first treatment. All experimental animals were culled at 21 days
post-challenge, lungs were excised and homogenized in PBS
0.1% w/v Triton X-100 in a Precellys homogeniser (Bertin
Instruments, Montigny-le-Bretonneux, France), and serial
dilutions were plated in duplicates on 7H11 agar plates to
enumerate CFU.
IgA Detection in TB Patient Sera
Studies on sera samples from the TB patient and their contacts
cohort in Mozambique were approved by the Ministry of Health
Committee of Bioethics and Health 9ref 298/CNBS/15. Serum
samples were collected and sterile filtered using 0.22 µm PES
filters (Millex). Antigen binding ELISA was carried out by
coating ELISA plates (NUNC) with Acr or MPT64 at 5 µg/ml
overnight and detecting antigen specific serum IgA with an HRPFrontiers in Immunology | www.frontiersin.org 4conjugated anti-human a-chain antibody (The Binding Site).
ELISA plates were developed with SigmaFast OPD (Sigma) and
absorbance was read at 495nm.
Statistical Analysis
All statistical analyses were carried out using Graphpad Prism 8.
Multivariance one-way ANOVA was used for multiple
comparisons followed by post-hoc group-to-group comparisons
as indicated in figure legends. Differences were considered
significant when the p value was equal or less than 0.05.RESULTS
2E9IgA1 Binding Studies
The 2E9IgA1 mAb was expressed in CHO cells as described
previously (10). The purified antibody migrated as a 160 kDa
protein band under non-reducing conditions and as 55 kDa
(alpha chain) and 25 kDa (kappa chain) protein bands under
reducing conditions, as shown by Coomassie staining orWestern
blot (Figure 1A). 2E9IgA1 was fully functional as determined in
direct antigen binding assay (Figure 1B) and bound specifically
to the surface of BCG as confirmed by flow cytometry (Figures
1D, G), while no binding could be observed with E. coli (Figures
1C, F). This binding to mycobacteria was Acr specific since
increasing concentrations of soluble Acr antigen progressively
inhibited it to near completion (Figures 1E, H). Thus, using
BCG as a surrogate pathogen, we demonstrate dose dependent
surface binding of 2E9IgA1 which could not be observed with
E. coli.
Intranasal Inoculation of 2E9IgA1 in Mice
Considering that CIT was to be applied mucosally, we wanted to
determine persistence of the 2E9IgA1 mAb following intranasal
application to CD89 Tg mice. Mice were inoculated 50 mg of 2E9
mAb and 1 mg of murine IFN-g; and broncho-alveolar lavage
(BAL) recovered at different time points. To determine if CIT
alters the lung cytokine milieu following mycobacterial challenge,
CIT was also co-applied with BCG (0.5 million CFU). As can be
seen in Figure 2A, 2E9IgA1 mAb can be recovered from BAL up
to 150 h later with the half-life being 75 h. Presence of BCG only
marginally decreased the half-life of 2E9IgA1 mAb in the BAL
(60 h). We then analyzed selected cytokine and chemokine
concentrations in BAL at 75 h post treatment. As expected, we
could detect a significant amount of IFN-g; (Figure 2B), which is
likely to be largely the exogenously applied IFN-g;. We also
observed an increase in TNF when BCG was co-applied with
CIT compared to BCG alone (Figure 2C) although this difference
was not statistically significant. No statistically significant
difference was seen in IL-6 response between BCG and BCG +
CIT groups (Figure 2D). Interestingly, despite exogenous IFN-g
administration in CIT-treated animals, levels of CXCL10 did not
increase significantly compared to PBS-treated animals as
expected (Figure 2E). The most striking difference, however,
was a dramatic increase in the levels of CXCL10 in BCG + CIT
BAL compared to BCG alone (Figure 2E). We also observed aOctober 2020 | Volume 11 | Article 582833
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FIGURE 1 | Biophysical characterisation of 2E9IgA1. SDS-PAGE Coomassie and Western blot (A) were performed under non-reducing (NR) and reducing (R)
conditions. a and k chains were detected using HRP conjugated anti-human a and k chain secondary antibodies and developed with ECL prime substrate. 2E9IgA1
binding to purified recombinant Acr antigen was investigated by ELISA (B) with error bars indicating SEM. Binding of 2E9IgA1 to (E) coli (C, F) and BCG (D, G) was
investigated by flow cytometry using an anti-human IgA (a-chain) FITC conjugated antibody and acquired on a BD FACSCalibur. Antigen specificity of 2E9IgA1 binding to
BCG was performed by an Acr competition assay prior to data acquisition by flow cytometry (E, H). Experiment performed two times, with similar outcomes.Frontiers in Immunology | www.frontiersin.org October 2020 | Volume 11 | Article 5828335
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levels in the CIT+BCG group compared to those receiving BCG
alone (Figure 2F).
Suppression of MDR-TB Infection
With 2E9IgA1
To test the therapeutic potential of combined 2E9IgA1 and IFN-
g; treatment (CIT), we infected mice with a clinical isolate of
MDR-TB by aerosol administration of 100 (exp. 1 and 3) or 200
(Exp.2) CFU. We then tested CIT in separate experiments using
three different regimens. The difference was in the start of the
treatment in relation to infection: at the time of pathogenic
challenge (Exp.1), 1 day after challenge (Exp.2) or 7 days after
challenge (Exp.3). In each experiment the treatment was given
two more times, 3 and 6 days later and mice culled at 3 weeks. AsFrontiers in Immunology | www.frontiersin.org 6can be seen in Figure 3, all three regimens resulted in a
statistically significant reduction of the infection, albeit to a
different degree. Thus, initiating CIT at the time of infection
gave the greatest (50-fold) reduction in lung CFU, while delaying
the start of the treatment to 1 and 7 days resulted in 10- and 5-
fold reduction. While we did not perform individual treatment
controls in these experiments due to restricted numbers of
available CD89 Tg animals, our previous work (10) and results
from Figure 5 (below) showed that while IFN-g; showed a trend
toward protection, it alone was not sufficient to induce a
statistically significant lung CFU reduction in any of our
experiments. On the other hand, while 2E9IgA1 alone is
somewhat protective (10), it combines best with IFN-g; to
induce the observed CIT-mediated suppression of infection in
additive or possibly synergistic fashion.A B
D
E F
C
FIGURE 2 | Persistence of nasally applied IgA in mice and cytokine response to CIT in BAL. CD89 transgenic mice were treated with intranasal PBS or CIT either
with or without prior intranasal BCG challenge. 2E9IgA1 titres in BAL fluids were determined by ELISA to assess persistence of exogenous 2E9IgA1 in the lungs of
mice (A), ** indicates p ≤ 0.01 using students t test. Cytokine levels in BAL fluids were quantified by a multiplex flow-cytometric assay and acquired on a BD
FACSCanto to determine IFN-g (B), TNF (C), IL-6 (D), CXCL10 (E), and CXCL1 (F) responses, *p ≤ 0.05, **p ≤ 0.01 using one-way ANOVA with Tukey’s correction.
Error bars indicate SEM of three biological samples.October 2020 | Volume 11 | Article 582833
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2E9IgA1 Mediated Protection
To elucidate the potential mechanisms that may contribute to
2E9IgA1 mediated protection against MDR-TB infection, we
focused on phagocytic uptake and the potential role of
neutrophils. First, we demonstrated that 2E9IgA1 promotes
phagocytic uptake by human THP-1 monocyte/macrophage
cell line (Figure 4A) so that Acr and PPD (mycobacterial
purified protein derivative) coated beads were taken up more
efficiently than HIV-derived p24 coated beads. This increased
phagocytic uptake appears to result in a better long-term control
(5 days) of intracellular mycobacterial infection, as shown in
Figure 4B. Similarly, though less efficient than macrophages,
human neutrophils also showed enhanced phagocytic uptake of
Acr and PPD-coated beads (Figure 4C). To elucidate the
potential role for neutrophils in IgA-mediated inhibition of
infection, we infected mouse macrophage J774 cells with M.
tuberculosis strain H37Rv in the presence of 2E9IgA1 or a control
IgA, and supplemented the cultures with human neutrophils for
24 h. Like macrophages, human neutrophils strongly express
CD89 receptor but their role in TB immunity is insufficiently
described. As can be seen in Figure 4D, the presence of
neutrophils (5:1 ratio to macrophages) appeared to
paradoxically increase the level of cell infection in this culture
system and this is likely due to neutrophils themselves becoming
infected or at least harbouring partially digested but still live
organisms. Nevertheless, while 2E9IgA1 did not show
statistically significant reduction of J774 cell infection, there
was a difference over control IgA in the presence of
neutrophils. The limitation in this experiment is the short half-Frontiers in Immunology | www.frontiersin.org 7life of neutrophils and inability to distinguish bacterial uptake
betweenmacrophages and neutrophils; nevertheless, these findings
seem to indicate that neutrophils may indeed play a role in a more
complex in vivo environment and that they may contribute to the
therapeutic effect of CIT in CD89 transgenic mice.
Lack of Protection by the 2E9IgG1
Anti-Acr mAb
Since effector functions of FcR gamma and alpha antibody chains
differ significantly, we next wanted to test if the IgG version of
the same antibody would also be protective. If so, this could be a
potential advantage in translation of this approach to clinical
treatment of MDR-TB, since unlike IgA, there are numerous
licensed IgG-based treatments against various conditions (21,
22). In addition to a fully functional 2E9IgG1, we also generated
a mutant of the mAb (LALA) which cannot bind to human Fc-
gamma receptor. We tested these two versions of 2E9IgG1 mAb
in transgenic mice expressing the human Fcg;R1 receptor
(CD64). This being an IgG, we modified the treatment
regimen to include one bolus peritoneal injection, preceded
and followed by an intranasal administration, again in
combination with IFN-g;. We also used a control IgG1 (Sigma)
as an additional negative control. As can be seen in Figure 5,
none of the treatments induced statistically significant reduction
of lung CFU, although a trend toward reduction compared to no
treatment control (PBS) was observed. While the treatment
regimen was modified in this experiment and a different strain
of transgenic mice was used, we took these outcomes to mean
that IgA exerts superior therapeutic potential over IgG under the
specific experimental conditions in our studies.FIGURE 3 | CIT treatment of aerosol MDR-TB challenge in CD89 transgenic mice. CD89 transgenic BALB/c mice were challenged with 100–200 CFU MDR-TB by
the nose-only aerosol challenge method. Animals were given treatment of 50 µg/animal 2E9IgA1 + 1 µg/animal IFN-g (CIT) either on the day of challenge (Exp.1),
24 h post challenge (Exp. 2) or 7 days post challenge (Exp. 3), with the two subsequent intranasal doses at three-day intervals. Animals were culled at 3 weeks post-
challenge and lung CFU were enumerated. Error bars indicate SEM. *p ≤ 0.05, ****p0.0001 as determined by one-way ANOVA with Tukey’s correction; n = 8. Three
independent experiments.October 2020 | Volume 11 | Article 582833
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Patients and Healthy Controls
We expanded our analysis to humans, by testing the levels of IgA
antibodies in sera of TB patients. Anti-Acr IgA ELISA was
performed on serum samples from 21 TB patients, 17 exposed
contacts, and 19 uninfected healthy controls from a study cohort in
Maputo, Mozambique. All participants were vaccinated with BCG
at birth as per national guidelines, and this could be confirmed by a
visible scar in the majority. We also tested these sera for antibodies
against the virulence associated factor MPT-64 antigen.
Serum IgA antibody levels (Figure 6) to Acr were well
demonstrable and notably, and they were found to be of
similar magnitude in all three tested groups. In sharp contrast,
IgA response to MPT-64 strongly elevated in active TB patients,
while the LTBI individuals and uninfected controls showed no
responses apart from a small proportion of participants who
displayed a weak response.
Assessing the Feasibility of Aerosol
Delivery for 2E9IgA
With a view to move toward initiating human clinical trials for
CIT, a delivery system suitable for human application must be
considered. To that end, we explored the use of aerosolization toFrontiers in Immunology | www.frontiersin.org 8deliver 2E9IgA to mucosal surfaces using the widely available
Omron Micro Air nebuliser. Antibodies are bioactive, relatively
large molecules, and the process of aerosolization in a nebulizer
may lead to loss of protein and/or activity (23). Indeed, when we
aerosolized 2E9IgA1, only 48% of the protein was recovered in the
condensate (Figure 7A) and this associated also with a significant
loss of antigen-binding capacity (Figure 7B) and receptor
coupling of the recovered protein (Figure 7C). However, these
losses were largely reversed by adding 0.01% Tween-20
(Polysorbate-20) to the antibody preparation so that only 12.4%
antibody was lost, coupled with a 13.5% loss of antigen binding
and 28.1% loss of receptor binding. These findings suggest that
aerosolized delivery of 2E9IgA using the Omron nebulizer is
feasible provided that a non-ionic detergent is included in the
formulation, although there is further scope for optimization.DISCUSSION
The present study demonstrated that CIT could suppress MDR-
TB infection in mice bearing the human IgA receptor. As
demonstrated in three different experimental scenarios, the
most significant therapeutic effect was observed when CITA B
DC
FIGURE 4 | In vitro 2E9IgA1 modulation of phagocytic uptake and mycobacterial infection. Macrophage THP-1 cell phagocytic uptake of beads opsonised with Acr
or PPD mediated by 2E9IgA1 at 0.5 µg/ml (A). Macrophage U937 monocyte infection with M. tuberculosis in the presence or absence of CIT (B); cells were infected
for five days and shown are the means + SEM of triplicate cultures. Human neutrophil uptake of beads opsonized with Acr (C). Infection of mouse J774 cells in the
presence of 0.1 µg/ml of 2E9IgA1 and human neutrophils (D); cells were infected with M. tuberculosis for 24 h and supplemented with neutrophils at a MOI of 5:1
for another 24 h; shown are the means of triplicate cultures + SEM. Neutrophil experiment performed once and macrophage/monocyte twice, with similar outcomes.
*p ≤ 0.05, **p ≤ 0.01 as determined by one-way ANOVA with Tukey’s correction.October 2020 | Volume 11 | Article 582833
Tran et al. Mucosal IgA Immunotherapy of Tuberculosistreatment was initiated at the time of infection. Importantly
though, we observed a significant reduction in lung CFU even
when the infection was allowed to establish, at 1-week post-
exposure. The mandatory role of the IgA isotype was suggested
by the lack of protection by the IgG version of 2E9IgA1 in Fc-
gamma receptor transgenic mice. Furthermore, our previous
work has shown that protection against Mtb challenge in
2E9IgA-treated mice was dependent on mice being transgenic
for the CD89 receptor (10). CD89 expression in transgenic
mice was previously detected on neutrophils, monocytes and weakly
positive on macrophages (24) which was similar to the expression
profile in found in humans (25). Given our understanding for the
different functional roles of IgA and IgG, these data imply that the
immune-function of IgA provides superior control over M.
tuberculosis compared to those exerted by IgG, although
differences in glycosylation between the two antibody isotypes
tested may also play a role. The superiority of IgA over IgG has
also been reported in other studies (5), but the present experimentsFrontiers in Immunology | www.frontiersin.org 9are the first to compare the two isotypes using antibodies of the
same epitope specificity. This IgA phenomenon may be most
important because of the mucosal nature of TB, where the innate
immune cells in the lung may be heavily involved in the
bacterial clearance.
The potential mechanisms involved were ascertained by the
demonstration that beads opsonised with 2E9IgA1 underwent
enhanced phagocytosis by macrophages and neutrophils.
Antibody mediated phagocytosis is known to enhance phago-
lysosomal fusion (26), circumventing the pathogen mediated
inhibition of this process, a prominent survival mechanism used
byM. tuberculosis (27). Interactions with antibody FcR and TLRs
(28, 29) activate host defence mechanisms while interactions
with complement receptors favour bacterial survival (30). FcgR
interaction activates signal transduction that increases
macrophage Ca2+ influx and subsequent intracellular killing
(31). Since 2E9IgA1 has been shown to improve bacterial
uptake by monocyte/macrophages, it is possible that this mayA B
DC
FIGURE 5 | Effect of 2E9IgG1 on aerosol MDR-TB challenge in CD64 transgenic mice. Recombinant 2E9IgG1 was characterized by SDS-PAGE Coomassie (A) and
Western blot (B) using HRP conjugated anti-human IgG (g-chain) secondary antibody. SDS-PAGE loading order was as follows: 1) 2E9IgG1 (NR), 2) 2E9IgG1 (R), 3)
2E9IgG1-LALA (NR), 4) 2E9IgG1-LALA (R), 5) human serum IgG (NR), and 6) Human Serum IgG (R). 2E9IgG1 and 2E9IgG1-LALA binding to Acr was investigated
by ELISA (C). CD64 transgenic BALB/c mice were challenged with 200 CFU MDR-TB by the nose only aerosol method, and treated with three doses of 2E9IgG1 +
IFN-g. The first dose consisted of 20 µg/animal of 2E9IgG + 1 µg/animal of IFN-g given intranasally. The second dose was given by the intraperitoneal route and
consisted of 40 µg/animal of 2E9IgG1 + 2 µg/animal of IFN-g. The third dose was given intranasally, as the first. Animals were culled 21 days after the MDR-TB
challenge and lung CFUs were enumerated (D). Error bars indicate SEM. N/S indicates no significance by one-way ANOVA with Tukey’s correction; n = 8. Mouse
experiment performed once.October 2020 | Volume 11 | Article 582833
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killing mechanisms, especially when combined with macrophage
activating IFN-g;. We also found that 2E9IgA1 improves
bacterial control in the presence of neutrophils although the
overall level of infection in this two-cell type co-culture system is
paradoxically increased. This was most probably due to some of
the bacteria being ingested by the neutrophils themselves but not
yet killed. Further studies are required to elucidate the role of
neutrophils in M. tuberculosis infection and the potential role of
antibodies in their mode of action.
Targeting of 2E9IgA1 to the 16kDa Acr antigen may be an
important determinant of its protective potential. Acr is
prominently expressed by M. tuberculosis inside macrophages,
under hypoxia-induced stress conditions (32), and is also
associated with dormancy (33). While its expression is mostly
confined to cytosol, it can be also found associated with cell wall
(33). For the purpose of our study, it was important to demonstrate
the availability of Acr antigen on the surface of mycobacteria, as aFrontiers in Immunology | www.frontiersin.org 10prerequisite for 2E9IgA1 mAb therapeutic activity. Indeed, we
showed that 2E9IgA1 could bind efficiently and in a dose-
dependent manner to BCG surface and that this could be inhibited
with soluble Acr. Thus, this establishes the Acr antigen as a novel
target for immunotherapy and is suggestive of possibly also other
non-classical cell wall proteins that could be targeted by
antibody treatments.
Evidence gathered from this and other studies points toward
beneficial effects from antibody-based combined immunotherapies
which could be exploited in conjunction with chemotherapy (9, 34–
38). Screening of the current and new antibiotics with monoclonal
antibodies may represent an untapped opportunity in the setting of
ever-increasing microbial drug resistance.
The field should now move toward the study of recombinant
human antibodies, with a view to initiating clinical trials. With
that in mind, we performed initial aerosolization studies with
2E9IgA1, to test the feasibility of this concept. Aerosolized, lung-
targeted delivery would be the most appropriate mode of deliveryA B
FIGURE 6 | IgA responses in patient serum samples from Instituto Nacional de Saúde, Mozambique. End point titres (EPT) (defined as 2-fold absorbance value of
background samples) of IgA in serum against Acr (A) and MPT64 (B) were determined by ELISA with error bars indicating SEM. ****p ≤ 0.0001, one-way ANOVA
with Tukey’s correction; n = 21 (TB patients), 17 (LTBI), and 19 (BCG vaccinated). Experiment performed once.A B C
FIGURE 7 | Assessing the feasibility of aerosolized delivery of 2E9IgA1. 1 ml of 100 µg/ml of 2E9IgA1 was nebulized using an Omron MicroAir U22 portable mesh
nebulizer, either in PBS alone or with 0.01% Tween-20. Condensate was collected, protein was recovered (A), and Acr binding by ELISA (B) and recombinant CD89
binding activity by ELISA (C) were investigated to compare original and nebulized samples with equal protein loading. Experiment performed twice, with similar results.October 2020 | Volume 11 | Article 582833
Tran et al. Mucosal IgA Immunotherapy of Tuberculosisof CIT as an adjunctive treatment of MDR-TB. Previous clinical
studies have demonstrated feasibility of aerosolized delivery of
IFN-g; to MDR-TB patients (39, 40) but no such evidence exist
for 2E9IgA1, or antibodies in general. We demonstrated that
with the addition of 0.01% Tween-20 into the antibody sample,
protein recovery, antigen binding activity and host Fc receptor
binding activity can largely be recovered from the condensate.
Tween-20 (and Tween-80, which showed similar results) is
permissible for human application in low concentrations and is
used in foods and medications as a dispersant or excipient (41,
42). These results demonstrated the feasibility of 2E9IgA1
aerosolized delivery and warrant further optimisation studies
to minimise these losses even further.
Testing serum IgA antibodies showed elevated anti-Acr levels in
LTBI and BCG vaccinated subjects. This finding is in accord with
the previous report that occupational TB exposure associated with
elevated antibody levels to Acr, but not to other immunodominant
antigens (43). Interestingly, another recent study reported an
increase of IgM anti-Acr antibodies in sera of LTBI individuals
(44) but that study did not include analysis of IgA. On the other
hand, the lack of further increase of anti-Acr IgA levels in sera of
active TBpatients can be interpreted as IgA-class selective, since the
increase of total antibodies in TB patients to this antigen can be
attributed to anti-Acr antibodies of the IgG isotype (45). The results
could be interpreted also with the assumption, that human IgA
antibodies directed against Acr epitopes are shared between M.
tuberculosis, BCG and non-tuberculous mycobacteria. In contrast,
anti-MPT64 antibody levels were selectively elevated in active
disease, but mostly below detection in LTBI- and BCG-vaccinated
subjects. Therefore, antibody profiling in various TB study groups
and populations may yield important new evidence for humoral
biomarkers of disease and immunity to infection. Likewise, itwould
be of interest to assess in future studies if antibiotic treatment may
see an elevation in Acr-specific IgA as a biomarker of response to
therapy and elimination of infection.
In summary, we show that recombinant human IgA-based
aerosolized delivery of CIT is feasible and deserves further
translation toward its potential contribution to the therapy of
MDR-TB. The protective attributes are further supported by the
finding of anti-Acr IgA antibodies in sera of LTBI- and BCG-
vaccinated individuals.Frontiers in Immunology | www.frontiersin.org 11DATA AVAILABILITY STATEMENT
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